When combined with potent antiplatelet agents and low-molecular-weight heparins, tenecteplase has demonstrated improved patient outcomes.
You are here
P&T® Journal contents for January 2003
The author reviews vaccine studies, combination rituximab trials, and developments with antisense therapy, proteosome inhibitors, and promising monoclonal antibodies.
Using a unit-specific pharmacist allows smaller hospitals to focus on patient care with greater flexibility and minimal increases in staffing.